Holen Sie sich die Stockscreener-App
29.10
0.14%
0.04
Handel nachbörslich:
29.06
-0.04
-0.14%
Schlusskurs vom Vortag:
$29.06
Offen:
$29.03
24-Stunden-Volumen:
38,470
Relative Volume:
0.35
Marktkapitalisierung:
$145.46M
Einnahmen:
$34.77M
Nettoeinkommen (Verlust:
$-74.04M
KGV:
-3.6304
EPS:
-8.0157
Netto-Cashflow:
$-79.76M
1W Leistung:
+3.08%
1M Leistung:
+5.66%
6M Leistung:
+226.87%
1J Leistung:
-31.12%
1-Tages-Spanne:
$28.72
$29.10
1-Wochen-Bereich:
$28.11
$29.20
52-Wochen-Spanne:
$5.21
$45.62
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
29.10 | 145.26M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | William Blair | Outperform |
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Luminus Management LLC Sells 989,314 Shares of Mersana Therapeutics, Inc. $MRSN - MarketBeat
Why Analysts See Mersana’s Story Shifting To Deal And CVR Outcomes After $1B Buyout - Yahoo Finance
Halper Sadeh LLC Encourages FFWM, MRSN, FSUN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
683 Capital Management LLC Boosts Stock Position in Mersana Therapeutics, Inc. $MRSN - MarketBeat
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc.MRSN - PR Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-SMLR, MRSN, CDTX, and RYI - The Malaysian Reserve
Day One Biopharmaceuticals Expands with Mersana Acquisition - StocksToTrade
Is Mersana Therapeutics Inc 0M4 a good long term investmentLarge Cap Stability Picks & High Return Trading Ideas - earlytimes.in
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI - Sahm
Mersana Therapeutics (MRSN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Is Mersana Therapeutics Inc. (0M4) stock prepared for digital transitionRate Hike & Daily Growth Stock Investment Tips - Newser
Can Mersana Therapeutics Inc. (0M4) stock stage a strong rebound this quarter - Newser
Can Mersana Therapeutics Inc. (0M4) stock sustain breakout momentumJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - Newser
Why Mersana Therapeutics Inc. (0M4) stock could be next leaderJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
How Mersana Therapeutics Inc. (0M4) stock compares with top peersQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
Will Mersana Therapeutics Inc. (0M4) stock attract long term capital inflowsJuly 2025 Review & Consistent Income Trade Ideas - Newser
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Will Mersana Therapeutics Inc. (0M4) stock deliver compounding returnsQuarterly Trade Report & Breakout Confirmation Alerts - Newser
Options Flow: How Mersana Therapeutics Inc. (0M4) stock compares with market leadersJuly 2025 Setups & Daily Technical Forecast Reports - moha.gov.vn
How Mersana’s Acquisition Is Changing the Story and Analyst Outlook for Investors - Yahoo Finance
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - Sahm
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
Is Mersana Therapeutics Inc. (0M4) stock a buy before new product rolloutJuly 2025 Rallies & Risk Controlled Daily Plans - moha.gov.vn
ENN Energy Holdings Announces Conditional Privatization Proposal - The Globe and Mail
683 Capital Management, LLC Increases Stake in Mersana Therapeutics Inc. - GuruFocus
Can Mersana Therapeutics Inc. (0M4) stock test all time highsJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Will Mersana Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 Trade Ideas & Safe Capital Growth Stock Tips - newser.com
Is Mersana Therapeutics Inc. (0M4) stock testing key supportEarnings Risk Report & AI Driven Stock Reports - newser.com
Does Mersana Therapeutics Inc. qualify in momentum factor screeningShort Setup & Low Drawdown Momentum Ideas - newser.com
Why Mersana Therapeutics Inc. stock remains a top recommendationEarnings Miss & Free Reliable Trade Execution Plans - newser.com
Earnings visualization tools for Mersana Therapeutics Inc.2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Will Mersana Therapeutics Inc. stock benefit from infrastructure spending2025 Analyst Calls & Safe Entry Point Alerts - newser.com
How Mersana Therapeutics Inc. (0M4) stock reacts to weak economyTrade Exit Summary & Safe Capital Growth Tips - newser.com
Detecting price anomalies in Mersana Therapeutics Inc. with AIWeekly Trade Report & Low Risk Entry Point Guides - newser.com
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):